Heilongjiang ZBD Pharmaceutical Co., Ltd.: history, ownership, mission, how it works & makes money

From its founding in 1996 in Hulin, Heilongjiang, Heilongjiang ZBD Pharmaceutical Co., Ltd. has grown from a regional Chinese-medicine maker into a publicly traded drugmaker (Shanghai ticker 603567) that by 2010 offered a diversified portfolio spanning cardiovascular, respiratory, orthopedic, oncology, digestive, anti-infection, mental nerve and genitourinary therapies, expanded into medicinal-herb cultivation in 2003, listed on the Shanghai Stock Exchange in 2015, built a distribution network covering over 30 Chinese provinces and select export markets by 2020, and by 2025 reported revenue of 2.70 billion CNY-a drop of 13.84% year-on-year-while holding an approximate market capitalization of 11.69 billion CNY in July 2025; its vertically integrated model (R&D, manufacturing, distribution), a workforce of more than 2,300 employees, R&D investment of about 10% of annual revenue, leadership under CEO Jiujiang Yan since 2020, and significant ownership by the Heilongjiang SASAC together shape how it operates, earns revenue from prescription and OTC drugs and herb processing, and pursues innovation and selective international expansion.

Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS): Intro

• Founded: 1996, Hulin, Heilongjiang Province
• Vertical expansion into cultivation/processing: 2003
• Broadened therapeutic portfolio by 2010
• Shanghai Stock Exchange listing: 2015 (603567.SS)
• Distribution reach: >30 Chinese provinces by 2020; began exports to select international markets

• Corporate status: publicly traded joint-stock company on Shanghai SSE (603567.SS).
• Shareholder composition: mix of institutional investors, domestic funds, and corporate insiders typical of SSE-listed peers (specific major-shareholder names and stakes available in company filings and the investor profile linked below).
• Governance: board of directors and supervisory board consistent with PRC listed-company structure; executive management focuses on TCM R&D, supply chain integration, and sales expansion.

• Mission: develop and deliver traditional Chinese medicine products that combine cultivated medicinal material with modern R&D and manufacturing to serve domestic and selected international markets.
• Strategic priorities: vertical integration (cultivation → processing → production), broad therapeutic portfolio, strengthen hospital and retail distribution, selective export growth.
• Core capabilities: own herb cultivation bases, GMP manufacturing, registered TCM product lines across multiple therapeutic areas, established sales network covering >30 provinces.

• Raw material control: owns/partners cultivation bases to secure medicinal herb supply and reduce input volatility.
• Processing & manufacturing: in-house processing and GMP production plants to convert herbs into finished forms (extracts, pills, capsules, injections where applicable).
• R&D & registration: product development, clinical/registration work for prescription and OTC TCM formulations.
• Sales & distribution: multichannel - hospital procurement, retail pharmacies, distributors and regional sales teams; exports via selected international partners.

• Product sales - prescription and OTC TCM medicines across multiple therapeutic areas (cardiovascular, respiratory, orthopedic, oncology, digestive, anti-infection, mental nerve, genitourinary).
• Bulk herb and processed material sales from own cultivation/processing operations.
• Distribution and logistics services to downstream channels (regional distributors, hospital supply chains).
• Export sales to a limited number of overseas markets initiated from 2020 onwards.
• Potential licensing/tech-transfer and contract manufacturing (depending on product and partner arrangements).

• 2025 revenue decline of 13.84% suggests pressure from pricing, competition, reimbursement policies, or lower volumes in core channels - common headwinds across Chinese pharma in certain years.
• Vertical integration (own cultivation and processing) helps control raw-material cost volatility and supports margin management versus pure-play distributors.
• Export initiatives provide diversification but likely remain a smaller share of total revenue as of 2025.

Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS): History

Founded in Heilongjiang province, Heilongjiang ZBD Pharmaceutical Co., Ltd. evolved from a regionally focused drug manufacturer into a listed pharmaceutical group serving domestic markets with specialty formulations and APIs. The company's development has followed China's broader state-led industrial modernization and mixed-ownership reform path, retaining significant state ownership while attracting private and institutional capital.

• Listing: Publicly traded on the Shanghai Stock Exchange under ticker 603567.SS.
• Market capitalization (July 2025): ~11.69 billion CNY.
• Largest shareholder: Heilongjiang State-owned Assets Supervision and Administration Commission (SASAC), holding a substantial controlling stake.
• Management ownership: CEO Jiujiang Yan (in office since 2020) and executive team hold a minority stake.
• Investor base: Diverse mix of domestic institutional and individual investors, reflecting mixed-ownership reform policies.

Mission and strategic focus:

• Deliver reliable pharmaceutical products and active pharmaceutical ingredients (APIs) to domestic healthcare providers and distributors.
• Leverage state support and private capital to upgrade manufacturing, R&D, and regulatory compliance.
• Expand product mix toward higher-value formulations and specialized therapeutics while maintaining stable generic production.

How the company works and makes money:

• Manufacturing and sales of pharmaceuticals and APIs to hospitals, pharmacies, and distribution partners - primary revenue drivers.
• Contract manufacturing and supply agreements with regional healthcare systems and distributors generate steady, volume-based income.
• R&D and pipeline development aim to capture higher-margin branded or specialty products over time, improving profitability.
• Operational scale and state-backed relationships help secure procurement contracts and favorable access to regional markets.

For more investor-focused details, see: Exploring Heilongjiang ZBD Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?

Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS): Ownership Structure

• Commitment to high-quality pharmaceutical products that enhance patient outcomes.
• Emphasis on innovation, technology and R&D investment to drive new therapies.
• Integration of traditional Chinese medicine practices with modern drug development.
• Stringent quality control, GMP adherence and regulatory compliance across production.
• Cultivation of continuous improvement, sustainability and long-term industry growth.
• Mission-driven strategic decisions focused on scaling healthcare impact and market position.

• R&D and product development: develops both TCM-based and modern pharmaceutical products, allocating a portion of revenue to in-house and collaborative R&D.
• Manufacturing and quality-controlled production: revenue generated from contract manufacturing and sale of proprietary drugs and health products.
• Domestic sales and hospital/retail distribution: primary sales channels include hospitals, pharmacies and provincial medical procurement systems.
• Export and partnership channels: selective international sales and joint ventures/licensing for broader market reach.

• Corporate governance aligns with Shanghai exchange requirements; board includes management and independent directors to oversee strategy and compliance.
• Major shareholders often include regional state-owned enterprises or investment vehicles plus strategic pharmaceutical partners and public investors.
• Dividend policy and capital allocation prioritize reinvestment into R&D and production capacity while balancing shareholder returns.

Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS): Mission and Values

• Core mission: develop affordable, effective pharmaceuticals with rigorous quality control and sustained R&D investment.
• Values: scientific integrity, patient safety, continuous innovation, and collaboration with academic partners.

• R&D: Allocates approximately 10% of annual revenue to research and development to advance new formulations, generics, and specialty compounds.
• Manufacturing: Operates multiple GMP-compliant production facilities equipped with modern production lines for APIs, formulations, sterile products, and solid-dosage forms.
• Distribution: Maintains a nationwide distribution network covering over 30 provinces in China and selective international markets via export and partner distributors.
• Collaborations: Partners with universities and research institutes to co-develop new molecules, clinical programs, and formulation technologies.
• Workforce: Supported by a dedicated team of more than 2,300 employees spanning R&D scientists, production staff, quality assurance, and commercial teams.

• Geographic reach: Over 30 Chinese provinces plus export channels into ASEAN nations, parts of Russia and CIS markets, and select African markets.
• Manufacturing footprint: Multiple facilities (manufacturing sites: 5-8, depending on product lines) with advanced equipment for oral solids, injectables, and APIs.

• Finished pharmaceutical products (branded generics and OTC): primary revenue driver.
• Active pharmaceutical ingredients (APIs): sold to internal and external customers.
• Contract manufacturing and private-label production for third parties.
• Collaborative R&D and licensing income from partnered innovations and technology transfers.

• Formal collaborations with regional universities and national research institutes to accelerate preclinical and clinical development.
• Joint projects often focus on formulation improvements, bioequivalence studies, and novel delivery systems.
• R&D pipeline supported by internal teams and external CROs for clinical and regulatory tasks.

• Vertical integration reduces time-to-market and improves margin capture across the value chain.
• Consistent R&D reinvestment (~10% of revenue) sustains product lifecycle renewal and differentiation.
• Nationwide distribution plus selective export markets provide diversified demand channels.
• Manufacturing scale and multiple facilities enable flexible production capacity and contract manufacturing services.

• Academic partners: provincial universities and specialized pharmaceutical research centers.
• International partners: distributors and licensing partners in ASEAN, Russia/CIS, and Africa.

Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS): How It Works

• Core product lines: cardiovascular, respiratory, orthopedic, oncology, digestive, anti-infection, mental nerve, and genitourinary medications.
• Vertical integration: proprietary herbal cultivation and processing facilities feed API and TCM production lines.
• Sales channels: hospital tenders, retail pharmacies (OTC), distributors, and exports to neighboring markets.
• Supporting functions: centralized quality control, regulatory affairs, and a domestic R&D center focused on formulation and bioequivalence studies.

• Finished-product sales - prescription and OTC drugs sold through hospitals and pharmacies: typically the largest revenue stream.
• Traditional Chinese Medicine (TCM) products - value added by in-house cultivated herbs lowers cost of goods sold and supports higher gross margins on TCM lines.
• API and herbal raw-material sales - external customers and third-party processors purchase processed herbs and intermediates.
• Export sales - selective international markets (regional export partners) diversify currency and market exposure.
• R&D-driven lifecycle management - reformulations, extended-release products, and generics/innovative preparations sustain market share and pricing power.

• Revenue mix estimate: finished products ~60-75%, TCM/herbal products & raw materials ~15-30%, exports & services ~5-15%.
• R&D intensity: pharmaceutical peers typically invest ~3-8% of revenue in R&D; Heilongjiang ZBD prioritizes formulation and generic development within this band.
• Gross margin drivers: in-house herb cultivation and integrated processing can lift gross margins by several percentage points versus fully outsourced peers.
• Working capital: inventory of raw herbs and finished goods is seasonal and tied to cultivation cycles; tight inventory management affects cash conversion.
• Regulatory sensitivity: reimbursement policy, hospital procurement rules, and generic substitution programs materially influence price and volume.

• Herb cultivation & processing: controlled agricultural sites produce standardized botanical inputs.
• R&D and formulation: internal teams adapt APIs and herbs into prescription, OTC, and TCM formulations.
• Manufacturing: GMP-compliant facilities produce finished dosages and semi-finished intermediates.
• Quality & regulatory: stability testing, batch release, and dossier submissions secure market access.
• Commercialization: hospital tender participation, pharmacy distribution, export logistics, and marketing.
• After-sales: pharmacovigilance and product lifecycle management to sustain market position.

• Market demand by therapeutic area (e.g., aging-driven cardiovascular demand vs. price-sensitive anti-infectives).
• Regulatory changes including national reimbursement lists, generic substitution policies, and export/import regulations.
• Competitive landscape - domestic generics competition and multinational entrants affect margins and volumes.
• Raw material supply and cultivation yields - climatic or agricultural risks can affect cost and availability of herbs.
• Currency and trade conditions for export revenue and cross-border procurement.

Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS): How It Makes Money

• Core revenue: sales of finished drugs (generic and proprietary formulations) to domestic hospitals, clinics and pharmacies.
• Manufacturing & supply: contract manufacturing for third parties and bulk pharmaceutical ingredient (API) sales.
• Licensing and collaboration: milestone and royalty income from partnerships and out‑licensing of developed compounds.
• Export sales: emerging contribution from international shipments and cross‑border distribution agreements.

• Position: Recognized in China for a comprehensive product portfolio and a reputation for quality manufacturing and compliance.
• Challenges: Faces revenue volatility and increasing competition-highlighted by a 13.84% revenue decline in 2024 compared with the prior year.
• R&D & innovation: Continuing investments in drug discovery and formulation improvement to support higher-margin proprietary products.
• International expansion: Exploring export channels and strategic partnerships to diversify revenue beyond the domestic market.
• Operational improvements: Ongoing initiatives to enhance manufacturing efficiency, reduce costs and upgrade quality systems to meet evolving healthcare standards.